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735Abstracts
philiacs (1810€) and was greater for patients in recombinant
treatment (2421€) to plasma derived (1001€). Compared to
moderate hemophiliacs, severe hemophiliacs placed a higher
value on the decrease in the risk of developing inhibitors (1033€
vs. 518€) and on the infusion frequency (706€ vs. 144€). The
employment status played an important role on monetary values
attributed to way of distribution: employed patients placed a
higher monetary value to “home delivery” (1495€) and “ofﬁce
pharmacy distribution” (2589€) compared to self-employed
patients (541€ and 89€, respectively) and to unemployed patients
(1002€ and 928€). CONCLUSIONS: We demonstrate that clin-
ical and socio-demographic characteristics inﬂuenced patients’
preferences. One of the practical utilities of conjoint analysis
consist in the capability of target different group with different
characteristics that consequently require different therapeutic
decisions. This allow to plan optimal hemophilia care.
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OBJECTIVES: Diabetes mellitus (DM) is a cluster of metabolic
disorders, requiring chronic care. Cockram et al found that 1) a
majority (62%) of those diagnosed with type 2 DM did not have
access to programs providing patient education in Hong Kong,
and 2) an alarming proportion (~50%) of patients with diabetes
were not sufﬁciently informed about the risk of complications.
The purpose of this study is to investigate the relationship of DM
patients’ medical knowledge and adherence to medical advice to
their glycaemic control. METHODS: The study adopted the
prospective, observational study design. Patients with DM who
were followed up at the specialist outpatient clinic at the Princes
of Wales Hospital were recruited. Two sets of Chinese question-
naires published in Yung et al were used to assess patients’ 1)
knowledge of DM, adherence to medical advice (maximum score
= 10) and 2) knowledge of signs and symptoms of hypoglycaemic
attacks (maximum score = 13). Demographic information, gly-
cosylated haemoglobin A1C (HbA1C) levels and any previous
history of hypoglycaemic attacks were recorded. Pearson
product-moment correlation coefﬁcients were used to identify
the associations between knowledge, adherence to medical
advice and glycaemic control (SPSS, 11.5.1, Chicago). RESULTS:
A total of 178 medical records were screened and 119 patients
(53% male; age: 62.2 ± 11.7 years old; mean duration of DM:
6.8 years) were recruited. The mean HbA1C level was 7.64 ±
1.55 %. The mean scores for the 2 questionnaires were 5.30 ±
1.88 and 4.29 ± 3.07 respectively. The correlation coefﬁcients
between the scores and the HbA1C levels were 0.024 and -0.061
respectively (P > 0.05). Patients with previous history of hypo-
glycaemic attach scored signiﬁcantly higher in the second 
questionnaire (mean difference = -1.784, P = 0.003). CON-
CLUSIONS: Patients’ knowledge on DM and adherence to
medical advice had no association with glycaemic control.
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OBJECTIVES: Several diabetes models have been developed to
determine cost-effectiveness of therapy, some of which predict
multiple complications. In these models, quality-adjusted life
years (QALY’s) have been estimated by multiplying health utility
scores for individual complications, largely due to a lack of
empirical data. This study evaluated the impact of this assump-
tion using empirical utility values to model multiple complica-
tions in patients with type-2 diabetes. METHODS: This study
used the Cardiff Stochastic Simulation Cost-Utility Model (Dia-
bForecaster), which follows 10,000 newly diagnosed patients
with type-2 diabetes over 20 years. We included the most reli-
able estimates of diabetes-related health utility scores using data
from the Health Outcomes Data Repository (HODaR). The
model employed baseline risk proﬁles used by Eastman. Utility
scores were incorporated either multiplicatively (utility values for
multiple complications were calculated by multiplying utility
values for individual complications), or empirically (direct
empirical data were used for patients with 1 and 2 complications
and average utility decrements were used for subjects with ≥3
complications). QALY estimates were obtained assuming com-
prehensive (HbA1c = 7.2%) or standard care (HbA1c = 10%).
The discount rate for beneﬁt was 1.5%. RESULTS: There were
1965 (8.6%) patients with type-2 diabetes in HODaR. The
overall mean utility for diabetic patients was 0.564 (SD ± 0.319)
for males and 0.508 (SD ± 0.358) for females. This ranged from
0.716 (SD ± 0.267) in outpatients with no reported complica-
tions to 0.490 (SD ± 0.353) in those with ≥3 vascular events.
Over 20 years, predicted QALYs ranged from a mean of 8.3
(multiplicative) to 8.9 per patient (empirical) assuming compre-
hensive care. Under standard care, the QALYS ranged from 6.8
(multiplicative) to 7.9 per patient (empirical). CONCLUSIONS:
The model predicted variations >1 QALY depending on how the
utility estimates were incorporated. The method chosen to value
health utility for multiple complications in diabetes models can
affect cost-effectiveness estimates of diabetes-related therapies.
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OBJECTIVES: A recent clinical trial demonstrated non-inferior-
ity in HbA1c and hypoglycaemic events with insulin detemir
(IDet) compared to NPH in a basal/bolus regimen. Mean body
weight in the IDet group increased less than the NPH group (0.4
Kg vs. 1.3Kg respectively p = 0.017). The aim of this analysis
was to use a validated diabetes model to link these short-term
outcomes to long-term complication rates and associated UK
health care costs, and to calculate the cost-effectiveness of treat-
ment with IDet in type-2 diabetes. METHODS: A validated,
non-proprietorial model, The Core Diabetes Model, was used to
predict: long-term complications; improvements in Life Years
